Source comparison
AOD-9604 vs MOTS-c: Research Applications Comparison
Primary Mechanism Beta-3 adrenergic receptor agonism → cAMP-mediated lipolysis in adipocytes AMPK activation + nuclear translocation → insulin sensitivity + mitochondrial biogenesis AOD-9604 acts peripherally on fat cells; MOTS-c acts systemically on metabolic
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Beta-3 adrenergic receptor agonism → cAMP-mediated lipolysis in adipocytes
- AMPK activation + nuclear translocation → insulin sensitivity + mitochondrial biogenesis
- AOD-9604 acts peripherally on fat cells; MOTS-c acts systemically on metabolic regulation
- Target Tissue
- White adipose tissue (WAT), primarily abdominal and visceral fat depots
- Skeletal muscle, liver, adipose tissue, hypothalamus
- MOTS-c has broader tissue distribution and crosses the blood-brain barrier
- Metabolic Endpoint
- Increased lipolysis, elevated plasma free fatty acids, reduced adipocyte triglyceride content
- Improved glucose tolerance, enhanced insulin sensitivity, increased mitochondrial respiration
- AOD-9604 measures fat mobilization; MOTS-c measures glucose handling and energy efficiency
- Anabolic Effects
- None. No IGF-1 stimulation, no effect on lean mass or bone density
- Mild anabolic signaling through AMPK-mTOR crosstalk in muscle tissue during resistance training contexts
- MOTS-c may support lean mass retention under caloric restriction. AOD-9604 does not
- Dosing Frequency (Research Models)
- Twice daily (due to 4–6 hour half-life)
- Once daily (cellular uptake and nuclear retention extend functional duration)
- MOTS-c offers dosing convenience in extended protocols
- Clinical Trial Evidence
- Phase II human trials for obesity showed significant visceral fat reduction vs placebo (Heffernan et al., 2005)
- Preclinical rodent and primate models; limited human data as of 2026
- AOD-9604 has more advanced human trial data; MOTS-c evidence is primarily animal-based
- Here's the honest answer: the difference between AOD-9604 and MOTS-c determines research design more than outcome. If the hypothesis centers on adipocyte-specific lipolysis without systemic metabolic intervention, AOD-9604 is the appropriate tool. If the research question involves insulin resistance, mitochondrial dysfunction, or metabolic syndrome models, MOTS-c addresses those pathways directly. Researchers who conflate the two are missing the mechanistic distinction. It's not 'which peptide burns more fat,' it's 'which metabolic pathway are you studying.'